These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30648923)

  • 21. Post-vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation.
    Mesfin YM; Cheng AC; Enticott J; Lawrie J; Buttery J
    Aust N Z J Public Health; 2021 Apr; 45(2):101-107. PubMed ID: 33617131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015.
    Pillsbury A; Cashman P; Leeb A; Regan A; Westphal D; Snelling T; Blyth C; Crawford N; Wood N; Macartney K;
    Euro Surveill; 2015; 20(43):. PubMed ID: 26536867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season.
    Chabanon AL; Wague S; Moureau A; Nissila M; Serradell L
    BMC Public Health; 2021 Feb; 21(1):358. PubMed ID: 33588815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.
    de Lusignan S; Tsang RSM; Akinyemi O; Lopez Bernal J; Amirthalingam G; Sherlock J; Smith G; Zambon M; Howsam G; Joy M
    JMIR Public Health Surveill; 2022 Mar; 8(3):e25803. PubMed ID: 35343907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
    Banzhoff A; Haertel S; Praus M
    Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance.
    Petousis-Harris H; Poole T; Turner N; Reynolds G
    Vaccine; 2012 Jul; 30(33):4945-52. PubMed ID: 22664224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluarix quadrivalent vaccine for influenza.
    Graaf Hd; Faust SN
    Expert Rev Vaccines; 2015; 14(8):1055-63. PubMed ID: 26098443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
    Choe YJ; Cho H; Kim SN; Bae GR; Lee JK
    Vaccine; 2011 Oct; 29(44):7727-32. PubMed ID: 21827815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010.
    Folkenberg M; Callréus T; Svanström H; Valentiner-Branth P; Hviid A
    Vaccine; 2011 Feb; 29(6):1180-4. PubMed ID: 21172382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21.
    Syrkina O; Inamdar A; Wague S; Monfredo C; Nissilä M; Chabanon AL; Serradell L
    BMC Public Health; 2022 Aug; 22(1):1506. PubMed ID: 35941631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.
    Lee GM; Greene SK; Weintraub ES; Baggs J; Kulldorff M; Fireman BH; Baxter R; Jacobsen SJ; Irving S; Daley MF; Yin R; Naleway A; Nordin JD; Li L; McCarthy N; Vellozzi C; Destefano F; Lieu TA;
    Am J Prev Med; 2011 Aug; 41(2):121-8. PubMed ID: 21767718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
    Lawrence GL; Boyd I; McIntyre PB; Isaacs D
    Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study.
    Tsang RS; Joy M; Byford R; Robertson C; Anand SN; Hinton W; Mayor N; Kar D; Williams J; Victor W; Akbari A; Bradley DT; Murphy S; O'Reilly D; Owen RK; Chuter A; Beggs J; Howsam G; Sheikh A; Hobbs FR; de Lusignan S
    Euro Surveill; 2023 Jan; 28(3):. PubMed ID: 36695484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.